Aldeyra Therapeutics
Todd C. Brady is the current CEO & President at Aldeyra Therapeutics. Prior to this, they were a Principal and Entrepreneur in Residence at Domain Associates from November 2004 to October 2013.
Todd C. Brady received their Doctor of Medicine from Duke University School of Medicine, their Doctor of Philosophy in Pathology from Duke University Graduate School, and their Bachelor of Arts in Philosophy and Psychology from Dartmouth College.
Stephen G. Machatha - Senior Vice President, Technical Operations, Lise L. Kjems - Vice President, Clinical Development, and Christopher Pearson - Vice President, Commercial Development and Strategy report to Todd C. Brady.
This person is not in any offices
Aldeyra Therapeutics
3 followers
Aldeyra Therapeutics develops treatments for aldehyde toxicity-related diseases including Sjögren-Larsson Syndrome (SLS) and noninfectious anterior uveitis.